N-(4-aminopyridin-3-yl)acetamide | 676464-96-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-aminopyridin-3-yl)acetamide
• CAS: 676464-96-3；750570-35-5
• 化学式: C₇H₉N₃O
• mdl: MFCD10699436
• 分子量: 151.17
• InChiKey: MKZXMKBJWHAKIX-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Methods of administering 3,4-diaminopyridine
  申请人：Garovoy Marvin R.

  公开号：US10793893B2

  公开（公告）日：2020-10-06

  Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

  本文提供了确定患有3,4-DAP敏感疾病的受试者的NAT乙酰化状态的方法、根据受试者的乙酰化状态选择3,4-DAP或其药学上可接受的盐的剂量的方法、向有需要的患者施用3,4-二氨基吡啶或其药学上可接受的盐的方法，以及治疗3,4-DAP敏感疾病的方法。
• COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY
  申请人：MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：EP3727587A1

  公开（公告）日：2020-10-28
• US20140255380A1
  申请人：——

  公开号：US20140255380A1

  公开（公告）日：2014-09-11
• Methods of Administering 3,4-Diaminopyridine
  申请人：SERB SA

  公开号：US20200407772A1

  公开（公告）日：2020-12-31

  Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
• [EN] METHODS OF ADMINISTERING 3,4-DIAMINOPYRIDINE<br/>[FR] MÉTHODES D'ADMINISTRATION DE 3,4-DIAMINOPYRIDINE
  申请人：BIOMARIN PHARM INC

  公开号：WO2013003708A1

  公开（公告）日：2013-01-03

  Provided herein are methods of determining NAT acetylation status of a subject with a 3,4- DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.